Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Sees Significant Decrease in Short Interest

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) saw a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 642,400 shares, a decrease of 55.7% from the January 15th total of 1,450,700 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is currently 6,424.0 days.

Wall Street Analysts Forecast Growth

Separately, Barclays upgraded Swedish Orphan Biovitrum AB (publ) to a “strong-buy” rating in a research note on Wednesday, January 8th.

Swedish Orphan Biovitrum AB (publ) Price Performance

BIOVF stock remained flat at $30.48 during midday trading on Friday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.49 and a current ratio of 0.73. The company has a 50 day simple moving average of $28.73 and a 200-day simple moving average of $28.84. The stock has a market cap of $10.85 billion, a P/E ratio of 51.66 and a beta of 0.53. Swedish Orphan Biovitrum AB has a twelve month low of $22.87 and a twelve month high of $32.25.

Swedish Orphan Biovitrum AB (publ) Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.